The global market for sickle cell disease treatment estimated to reach $5.6 billion by 2034, expanding at a double-digit CAGR of 28.6% over the forecast period, driven by high unmet clinical need for therapies that can reduce the frequency of vaso-occlusive crises (VOC) and prevent long-term organ damage.
Sickle cell disease (SCD) is a group of inherited red blood cell disorders characterized by the presence of abnormal hemoglobin, which causes red blood cells to become misshapen and rigid. This structural abnormality leads to a cascade of clinical complications, including chronic anemia, debilitating pain crises, and progressive organ damage.
